Clinical significance of the level of procalcitonin and C-reactive protein in patients with a new coronavirus infection.

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The dynamics of the level of procalcitonin and C-reactive protein at the inpatient stage of treatment of patients with a new coronavirus infection was assessed. The study included 885 patients who were divided into two groups depending on laboratory confirmation of coronavirus infection and into two subgroups according to the severity of its course. At the same time, each subgroup was divided into two more subgroups: at the time of discharge, patients of subgroup 1 had the level of procalcitonin and C-reactive protein within the normal range, patients of subgroup 2 had the level of procalcitonin within the normal range, and the level of C-reactive protein was more than 70% below the original value. The study did not reveal statistically significant differences between patients of the respective subgroups, as well as the effect of specific antiviral therapy on the levels of procalcitonin and C-reactive protein. It has been established that a decrease in the level of C-reactive protein by more than 70% lower than the baseline in patients with a new coronavirus infection of moderate and severe degrees can be used as a criterion for their transfer to the outpatient stage of treatment.

About the authors

I. V. Gonchar

The A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation

Author for correspondence.
Email: nachmed-60@mail.ru

подполковник медицинской службы

Russian Federation, Odintsovo, Moscow Region

R. N. Ovchinnikov

The A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation

Email: nachmed-60@mail.ru

подполковник медицинской службы

Russian Federation, Odintsovo, Moscow Region

A. V. Ershov

The V.A. Negovsky Research Institute of General Resuscitation of the Federal Scientific and Clinical Center for Resuscitation and Rehabilitation; The I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (the Sechenov University)

Email: salavatprof@mail.ru

доктор медицинских наук

Russian Federation, Moscow; Moscow

A. F. Sukhoterin

Health-resort «Zvenigorodsky» of the sports complex «Podmoskovye» of the Ministry of Defense of the Russian Federation

Email: nachmed-60@mail.ru

кандидат медицинских наук, подполковник медицинской службы запаса

Russian Federation, Zvenigorod, Moscow region

References

  1. Багирова Н.С., Петухова И.Н., Григорьевская З.В., и др. Преимущества и недостатки использования прокальцитонина в клинике // Злокачественные опухоли. – 2019. – № 9. – С. 32–42. DOI: org/10.18027/2224–5057–2019–9–3s1–32–42
  2. Глыбочко П.В., Фомин В.В., Авдеев С.Н. и др. Клиническая характеристика 1007 больных тяжелой SARS-CoV-2 пневмонией, нуждавшихся в респираторной поддержке // Клин. фармакол. тер. – 2020. – № 29. – С. 21–29. doi: 10.32756/0869–5490–2020–2–21–29
  3. Зайцев А.А., Чернов С.А., Стец В.В., Паценко М.Б., Кудряшов О.И., Чернецов В.А., Крюков Е.В. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре. Метод. реком. // Consilium Medicum. – 2020. – Т. 22, № 11. – С. 91–97.
  4. Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Функциональное состояние почек, уровни Д-димера и прокальцитонина крови при COVID-19 // Клин. нефрология. – 2020. – № 4. – С. 43–50.
  5. Сабиров И.С., Муркамилов И.Т., Фомин В.В. Гепатобилиарная система и новая коронавирусная инфекция (COVID-19) // The scientific heritage. – 2020. – № 49. – С. 49–58.
  6. Туличев А.А., Марасанов Б.О., Авилкин И.С. и др. Опыт применения ингибитора JAK-киназ в сочетании с низкими дозами преднизолона в лечении тяжелой коронавирусной инфекции // Мед. альманах. – 2021. – № 1. – С. 52–56.
  7. Чикина С.Ю., Бровко М.Ю., Роюк В.В., Авдеев С.Н. Нетипичное течение новой коронавирусной инфекции COVID-19 с поздним повышением уровня С-реактивного белка (клинические наблюдения) // Пульмонология. – 2020. – № 30. – С. 709–714. DOI: org/10.18093/0869–0189–2020–30–5–709–714
  8. Gao Y., Li T., Han M. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 // J. Med. Virol. – 2020. – N 92. – P. 791–796. doi: 10.1002/jmv.25770
  9. Lippi G., Plebani M. Laboratory abnormalities in patients with COVID-19 infection // Clin. Chem. Lab. Med. – 2020. – Vol. 58, N 7. – P. 1131–1134. doi: 10.1515/cclm-2020-0198
  10. Liu F., Li L., Xu M. et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 // J. Clin. Virol. – 2020. – N 127. doi: 10.1016/j.jcv. 2020.104370
  11. Ponti G., Maccaferri M., Ruini C. et al. Biomarkers associated with COVID-19 disease progression // Crit. Rev. Clin. Lab. Sci. – 2020. – Vol. 57, N 6. – P. 389–399. doi: 10.1080/10408363.2020.1770685
  12. Tan C., Huang Y., Shi F. et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early // J. Med. Virol. – 2020. – Vol. 92, N 7. – P. 856–862. doi: 10.1002/jmv.25871

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Gonchar I.V., Ovchinnikov R.N., Ershov A.V., Sukhoterin A.F.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.